Pharmaceutical Depyrogenation Equipment Market Report 2026

The pharmaceutical depyrogenation equipment market size has grown strongly in recent years. It will grow from $0.93 billion in 2025 to $1.01 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to increasing pharmaceutical production volumes, rising incidence of injectable drug manufacturing, demand for sterile glassware and containers, regulatory requirements for endotoxin-free products, adoption of conventional batch depyrogenation systems.

The pharmaceutical depyrogenation equipment market size is expected to see strong growth in the next few years. It will grow to $1.36 billion by 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to growth in vaccine and biologics production, adoption of automated and high-throughput depyrogenation equipment, increasing R&D in sterile manufacturing technologies, integration of advanced monitoring and IoT-based control systems, expansion of contract manufacturing organizations (CMOs) globally. Major trends in the forecast period include increasing demand for automated depyrogenation systems, rising adoption of high-temperature dry heat sterilization, expansion of depyrogenation equipment in vaccine and biologics manufacturing, growing focus on regulatory compliance and sterility standards, integration of real-time monitoring and process control systems.

The rising adoption of injectable pharmaceuticals is anticipated to propel the growth of the pharmaceutical depyrogenation equipment market in the coming years. Injectable pharmaceuticals refer to sterile drug formulations that are delivered directly into the body through syringes or infusion, bypassing the gastrointestinal tract. The use of injectable pharmaceuticals is increasing due to the growing prevalence of chronic conditions such as diabetes and cancer, which require prompt and efficient drug administration. Pharmaceutical depyrogenation equipment supports injectable pharmaceuticals by eliminating pyrogens and endotoxins from drug containers, thereby ensuring sterility and safeguarding patient health. For example, in July 2024, according to the United Nations Children's Fund (UNICEF), a US-based international organization providing humanitarian and developmental aid to children globally, the worldwide proportion of adolescent girls receiving at least one dose of the HPV vaccine increased from 20% in 2022 to 27% in 2023, representing a 7-percentage-point growth. Hence, the increasing adoption of injectable pharmaceuticals is contributing to the expansion of the pharmaceutical depyrogenation equipment market.

The growth of the biopharmaceutical and biotechnology sector is also expected to propel the pharmaceutical depyrogenation equipment market forward. The biopharmaceutical and biotechnology industry focuses on developing medical therapies using biological systems and drives innovation in drug discovery, vaccines, and treatments through technologies such as genetic engineering and molecular biology. The rapid advancement of this sector is primarily fueled by escalating investments in research and development of novel biologics, biosimilars, and advanced therapeutic solutions, which require strictly controlled and contamination-free manufacturing settings. The increasing scale of biopharmaceutical production reinforces the demand for depyrogenation equipment, as these systems are essential to maintaining endotoxin-free conditions necessary for the safe production of injectable medications, vaccines, and biological therapies. For instance, in January 2023, according to Cardinal Health Inc., a US-based healthcare company, the US had 33 FDA-approved biosimilar products as of January 2022, with 21 commercially available. By 2023, the number of FDA-approved biosimilars rose to 40, with 25 on the market. Therefore, the expansion of the biopharmaceutical and biotechnology industry is contributing to the growth of the pharmaceutical depyrogenation equipment market.

In June 2024, Syntegon Technology GmbH, a Germany-based provider of pharmaceutical processing and packaging equipment, acquired Telstar for an undisclosed amount. With this acquisition, Syntegon intends to expand its portfolio of integrated aseptic processing solutions and strengthen its technological capabilities in freeze-drying and containment systems to deliver end-to-end solutions for sterile pharmaceutical manufacturing. Telstar is a Spain-based provider of pharmaceutical equipment, including lyophilization systems, sterilization and depyrogenation solutions, isolators, and cleanroom engineering services.

Major companies operating in the pharmaceutical depyrogenation equipment market are STERIS Public Limited Company, Getinge Aktiebolag, Azbil Telstar Sociedad Limitada Unipersonal, Syntegon Technology Gesellschaft mit beschränkter Haftung, Belimed Aktiengesellschaft, Shibuya Corporation (Kabushiki Kaisha Shibuya Kogyo), OPTIMA Packaging Group Gesellschaft mit beschränkter Haftung, Marchesini Group Società per Azioni, Bausch + Ströbel SE & Co. Kommanditgesellschaft, Shanghai Tofflon Science and Technology Group Co. Ltd., Zhangjiagang Tofflon Machinery Co. Ltd., Fedegari Autoclavi Società per Azioni, Pharmalab India Private Limited, Steriline Società a responsabilità limitata, De Lama Società per Azioni, Dara Pharmaceutical Packaging S.A., Neelam Industries Private Limited, Lodha International Limited Liability Partnership, Stericox India Private Limited, Steelco.

North America was the largest region in the pharmaceutical depyrogenation equipment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmaceutical depyrogenation equipment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pharmaceutical depyrogenation equipment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pharmaceutical depyrogenation equipment market consists of sales of glassware depyrogenation units, stainless steel component depyrogenation systems, sterilization monitoring sensors, and cleanroom-compatible heating modules. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.